Q-omics provides the consensus-scored STPG4 profile across patient tissues and cancer cell-line models. STPG4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STPG4 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, STPG4 RNA expression shows 17,269 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where STPG4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STPG4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STPG4 survival associations across molecular data types. STPG4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STPG4 RNA expression–survival associations across cancer types. High STPG4 expression shows unfavorable associations in KIRC, BRCA, LGG, CESC and UCEC, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STPG4 RNA expression.
This table summarizes STPG4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for STPG4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STPG4 shows higher tumor expression in COAD, STAD, LUAD, PAAD, KIRC and READ. The COAD box plot shows higher STPG4 RNA expression in tumor versus normal tissue (log2 FC = +1.202, t-test p < 0.001).
This table shows molecular features associated with STPG4 in patient tissues and cancer cell lines. In patient samples, STPG4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STPG4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
